Shares of Natco Pharma fell over 2 per cent after it received seven observations in the Form-483 from the US Food and Drug Administration (USFDA). The pharma major's stock fell as much as 2.4 per cent ...

Natco Pharma’s active pharmaceutical ingredients unit in Chennai has received seven observations from the U.S. Food and Drug Administration. The U.S. FDA had conducted an inspection at the API ...

Natco Pharma on Friday, November 21, said the US Food and Drug Administration (FDA) has concluded its inspection of the company’s active pharmaceutical ingredient (API) manufacturing facility in ...

Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025. On ...

NATCO Pharma Limited has confirmed the successful completion of a US FDA inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility in Manali, Chennai. The inspection was carried ...

USFDA issues Form 483 with 7 observations to Natco Pharma's Chennai API unit after inspection. Details inside. New Delhi, Nov 21 (PTI) Natco Pharma on Friday said the US health regulator has issued ...

Stock market today: The domestic equity markets started on a softer note on Friday, influenced by widespread selling in global indices. The Nifty 50 opened at 26,109.55, reflecting a drop of -82.60 ...

https://www.thehindubusinessline.com/news/usfda-makes-7-observations-in-inspection-of-natco-pharmas-chennai-api-unit/article70307399.ece Copy The US Food and Drug ...

The Delhi High Court on Monday dismissed an application by FMC Corporation seeking to restrain Natco Pharma Limited from manufacturing and selling its insecticidal product “Cyantraniliprole 10.26% OD.

Natco Pharma’s Q2 FY26 sales were below estimates due to lower-than expected other operating income and domestic formulation business, while crop health was better than expected. PAT came above ...